CLEVELAND, Feb. 6, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 14th Annual BIO CEO & Investor Conference to be held Monday, February 13 through Tuesday, February 14, 2012, at the Waldorf Astoria in New York City.
Dr. Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys, is scheduled to present on Tuesday, February 14, 2012, at 9:00 a.m. Eastern Time. A live audio webcast of the presentation will be available via:
http://www.veracast.com/webcasts/bio/ceoinvestor2012/66203149.cfm.
Shortly thereafter, a webcast replay will be available via the Company's website at www.athersys.com in the Investors section.
About Athersys
Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft versus host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.
The Athersys, Inc. logo is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=4548